The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors

Leukemia

Volumn 9, Issue 6, 1995, Pages 1013-1024

  Dubrez, L ^a   Goldwasser, F ^b   Genne, P ^a   Pommier, Y ^a   Solary, E ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Cell cycle; Drug resistance; Leukemic cells; Topoisomerase

Indexed keywords

CAMPTOTHECIN; CYTOTOXIC AGENT; DNA FRAGMENT; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ENZYME INHIBITOR; ETOPOSIDE;

AGAR GEL ELECTROPHORESIS; APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE; CELL DEATH; CONTROLLED STUDY; CROSS LINKING; DNA DAMAGE; DNA STRAND BREAKAGE; ELECTRON MICROSCOPY; GENE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN DNA INTERACTION;

EID: 0029036445     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Liu LF. DNA topoisomerase poisons as antitumor drugs. Ann Rev Biochem 1989; 58: 351-375.
2. Kerrigan D, Pommier Y, Kohn KW. Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1 210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity. NCl Monogr 1987; 4: 117-124.
3. Pommier Y, Tanizawa A. Mammalian DNA topoisomerase I and its inhibitors. In: Hickmann J, Tritton T (eds). Cancer Chemotherapy. Blackwell Scientific Publications: Oxford, 1993; pp. 214-250.
4. Champlin R, Gale RP. Acute myelogenous leukemia: recent advances in therapy. Blood 1987; 69: 1551-1562.
5. Kantarjian H et al. Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 1993; 81: 1146-1151.
6. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res 1994; 54: 1431-1439.
7. Ishida R et al. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazzine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 1991; 51: 4909-4916.
8. Pommier Y et al. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 1994; 12: 530-542.
9. Gottesman M, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochcem 1993; 62: 385-427.
10. Arceci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993; 81: 2215-2222.
11. Danks MK et al. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemia cells selected for resistance to VM-26. Biochemistry 1988; 27: 8861-8869.
12. Ganapathi R et al. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topo II-mediated DNA cleavage. Cancer Commun 1989; 1: 217-224.
13. Cole SPC et al. Non-P-glycoprotein mediated resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topo II. Cancer Res 1991; 51: 3345-3352.
14. Fry A et al. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 1991; 51: 6592-6595.
15. Ganapathi R et al. Altered phosphorylation, biosynthesis and degradation of the 170 KDa isoform of topoisomerase II in amsacrine-resistant human leukemia cells: Biochem Biophys Res Commun 1993; 192: 1274-1280.
16. Bugg B, Danks M, Beck W, Suttle P. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemia cells selected for resistance to tenoposide. Proc Natl Acad Sci USA 1991; 88: 7654-7658.
17. Hinds M et al. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res 1991; 51: 4729-4731.
18. Patel S, Fisher LM. Novel selection and genetic characterisation of an etoposide-resistant human leukemia CCRF-CEM cell line: Br J Cancer 1993; 67: 456-463.
19. Kaufmann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposie, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 1989; 49: 5870-5878.
20. Lennon SV, Martin SJ, Cotter TG. Dose-dependent induction of apoptosis in human tumour cell lines by widely divergent stimuli. Cell Prolif 1991; 24: 203-214.
21. Solary E, Bertrand R, Kohn K, Pommier Y. Differential induction of apoptosis in undifferentiated and differentiated HL60 cells by DNA topoisomerase I and II inhibitors. Blood 1993; 81: 1359-1367.
22. Bertrand R, Solary E, Jenkins J, Pommier Y. Apoptosis and its modulation in human promyelocytic HL60 cells treated with DNA topoisomerase I and II inhibitors, Exp Cell Res 1993; 207: 388-397.
23. O'Connor P, Kohn K. A fundamental role for cell cycle regulation in the chemosenstivity of cancer cells. Semin Cancer Biol 1992; 8: 409-416.
24. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
25. Evans CA, Owen-Lynch PJ, Whetton AD, Dive C. Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells. Cancer Res 1993; 53: 1735-1738.
26. McGahon A et al. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83: 1179-1187.
27. Bertrand R et al. Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression. Cancer Res 1991; 51: 6280-6285.
28. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis In a human leukemia cell line. Blood 1993; 81: 151-157.
29. Walton M et al. Constitutive expression of human bcl-2 modulates nitrogen mustard and compothecin induced apoptosis. Cancer Res 1993; 53: 1853-1861
30. Kamesaki S et al. Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 1993; 53: 4251-4256.
31. Lotem J, Sachs L. Regulation by bcl-2, c-myc and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ 1993; 4: 41-47.
32. Kohn KW, Ewig RA, Erickson LC, Zwelling LA. Measurement of strand breaks and crosslinks by alkaline elution. In: Friedberg E, Hanawalt P (eds). DNA Repair: A Laboratory Manual of Research Procedures. Marcel Dekker: New York, 1981, pp 379-401.
33. Carmichael J et al. Evaluation of tetrazolium based semi-automated colorimetric assay/assessment of chemosensitivity testing. Cancer Res 1987; 47: 936-942.
34. Noonan KE et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990; 87: 7160-7164.
35. Chirgwin JM, Przybyla R, MacDonald J, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979; 18: 5294-5299.
36. D'Arpa P et al. cDNA cloning of human DNA topo I: catalytic activity of a 67.7-KDa carboxyl-terminal fragment. Proc Natl Acad Sci USA 1988; 85: 2543-2547.
37. Tan K et al. Topoisomerase IIα and topoisomerase IIβ genes: characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res 1992; 52: 231-234.
38. Erba HP, Gunning P, Kedes L. Nucleotide sequence of the human a-cytoskeletal actin mRNA: anomalous evolution of vertebrate non-muscle actin genes. Nucleic Acids Res 1986; 14: 5275-5294.
39. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
40. Mattern MR, Hofmann GA, Polsky RM, Johnson RK. Cross resistance of MDR, P-glycoprotein overexpressing CHO cells to camptothecin analogues. Proc Am Assoc Cancer Res 1993; 34: 324.
41. Hsiang YH, Lihou MG, Liu LF. Arrest of DNA replication by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 48: 5077-5082.
42. Sullivan DM et al. Proliferation dependence of topoisomerase II mediated drug action. Biochemistry 1986; 25: 2248-2256.
43. Chow KC, Ross WE. Topoisomerase-specific drug sensitivity in relation to cell cycle progression. Mol Cell Biol 1987; 7: 3119-3123.
44. Holm C, Covey JM, Kerrigan D, Pommier Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 1989; 49: 6365-6368.
45. Markovits J et al. Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH3T3 fibroblasts and L1210 leukemia cells. Cancer Res 1987; 47: 2050-2055.
46. Davies SM, Robson CN, Davies SL, Hickson ID. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins: J Biol Chem 1988; 263: 17724-17729.
47. Deffie AM, Batra JK, Goldenberg GJ. Direct correlation between DNA topoisomerase activity and cytotoxicity in Adriamycin-sensitive and resistant P388 leukemia cell lines. Cancer Res 1989; 49: 58-62.
48. Zwelling LA et al. Protein-associated deoxyribonucleic acid strand breaks produced in mouse leukemia L1210 cells by ellipticine and 2-methyl-9-hydroxy-ellipticinium. Biochem Pharmacol 1982; 31: 3261-3266.
49. Covey JM et al. Topoisomerase II-mediated DNA damage produced by 4′-(9-acridinyl-amino)methanesulfon-m-anisidine and related acridines in L1210 cells and isolated nuclei: relation to cytotoxicity. Cancer Res 1987; 48: 860-865.
50. Kaufmann SH et al. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 1994; 83: 517-530.
51. Chiron M et al: Sensitivity of fresh acute myeloid leukemia cells to etoposide: relationship with cell growth characteristics and DNA single-strand breaks. Blood 1992; 80: 1307-1315.
52. Caldecott K, Banks G, Jeggo P. DNA double-strand break repair pathways and cellular tolerance pathways to inhibitors of topoisomerase II. Cancer Res 1990; 50: 5778-5783.
53. Binashi M et al. Comparison of DNA cleavage induced by etoposide and doxorubicin in two small cell lung cancer lines with different sensitivities to topoisomerase II inhibitors, Int J Cancer 1990; 45: 347-353.
54. Gorczyca W et al. Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. Leukemia 1993; 7: 659-670.
55. Del Bino G, Skierski JS, Darzynkiewicz Z. Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1 210, MOLT-4) and myelogenous (HL60, KG-1) leukemia cells. Cancer Res 1990; 50: 5746-5750.
56. Del Bino G, Skierski J, Darzynkiewicz Z. The concentration-dependent diversity of effects of DNA topoisomerase I and II inhibitors on the cell cycle of HL60 cells. Exp Cell Res 1991; 195: 485-491.
57. Aller P et al. CPT induces differentiation and stimulates the expression of differentiation-related genes in U-937 human promonocytic leukemia cells. Cancer Res 1992; 52: 1245-1251.
58. Chou S, Kaneko M, Nakaya K, Nakamura Y. Induction of differentiation of human and mouse myeloid leukemia cells by camptothecin. Biochem Biophys Res Commun 1990; 166: 160-167.
59. Constantinou A, Kiguchi K, Hubermann E. Induction of differentiation and DNA strand breakage in human HL60 and K-562 leukemia cells by genistein. Cancer Res 1990; 50: 2618-2624.
60. Rius C et al. Differentiation of human promonocytic leukemia U937 cells with DNA topo II inhibitors: induction of vimentin gene expression. Mol Pharmacol 1990; 39: 442-448.
61. Del Bino G, Darzynkiewicz Z. Camptothecin, tenoposide, or 4′-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induce degradation of nuclear DNA in the S phase of HL60 cells. Cancer Res 1991; 51: 1165-1169.
62. Sugimoto K et al. Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood 1992; 79: 2378-2383.
63. Traganos F, Kapuscinski J, Darzynkiewicz Z. Caffeine modulates the effects of DNA-intercalating drugs in vitro: a flow cytometric and spectrometric analysis of caffeine interaction with novantrone, doxorubicin, ellipticine, and doxorubicin analogue AD198. Cancer Res 1991; 51: 3682-3689.
64. Boise L et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
65. Oltvai Z, Milliman C, Korsmeyer S. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
66. Smetsers T et al. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173: Leukemia 1994; 8: 129-140.
67. Lange W, Cantin EM, Finke J, Dölken G. In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA. Leukemia 1993; 7: 1786-1794.